Results 201 to 210 of about 20,669 (341)

Mitochondrial dysfunction: Related diseases, influencing factors, and detection

open access: yesInterdisciplinary Medicine, EarlyView.
Mitochondrial dysfunction is implicated in the pathogenesis of numerous diseases, including neurological disorders, cancers, and cardiovascular conditions, through mechanisms such as mitochondrial DNA mutations, dysregulation of mitochondrial network dynamics, and impaired mitophagy.
Zhaojin Li   +9 more
wiley   +1 more source

Structural Insights into Broad-Range Polyphosphate Kinase 2-II Enzymes Applicable for Pyrimidine Nucleoside Diphosphate Synthesis. [PDF]

open access: yesChembiochem
Kuge M   +11 more
europepmc   +1 more source

Examining the Impact of Diet‐and‐Exercise‐Induced Weight Loss on Drug Metabolism and Gastric Emptying in Patients with Obesity

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Obesity significantly influences drug pharmacokinetics (PK), which challenges optimal dosing. This study examines the effects of diet‐and‐exercise‐induced weight loss on key drug‐metabolizing enzymes and gastric emptying in patients with obesity, who frequently require medications for comorbidities.
Shuhan Liu   +8 more
wiley   +1 more source

Exploring and expanding the natural chemical space of bacterial diterpenes. [PDF]

open access: yesNat Commun
Wei X   +12 more
europepmc   +1 more source

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy